Chapter 1. Age-Related Macular Degeneration (AMD) Therapeutics Market – Scope & Methodology

1.1. Market Segmentation

1.2. Assumptions

1.3. Research Methodology

1.4. Primary Sources

1.5. Secondary Sources

Chapter 2. Age-Related Macular Degeneration (AMD) Therapeutics Market – Executive Summary

2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)

2.2. Key Trends & Insights

2.3. COVID-19 Impact Analysis

      2.3.1. Impact during 2023 – 2030

      2.3.2. Impact on Supply – Demand

Chapter 3. Age-Related Macular Degeneration (AMD) Therapeutics Market – Competition Scenario

3.1. Market Share Analysis

3.2. Product Benchmarking

3.3. Competitive Strategy & Development Scenario

3.4. Competitive Pricing Analysis

3.5. Supplier - Distributor Analysis

Chapter 4. Age-Related Macular Degeneration (AMD) Therapeutics Market - Entry Scenario

4.1. Case Studies – Start-up/Thriving Companies

4.2. Regulatory Scenario - By Region

4.3 Customer Analysis

4.4. Porter's Five Force Model

       4.4.1. Bargaining Power of Suppliers

       4.4.2. Bargaining Powers of Customers

       4.4.3. Threat of New Entrants

       4.4.4. Rivalry among Existing Players

       4.4.5. Threat of Substitutes

Chapter 5. Age-Related Macular Degeneration (AMD) Therapeutics Market - Landscape

5.1. Value Chain Analysis – Key Stakeholders Impact Analysis

5.2. Market Drivers

5.3. Market Restraints/Challenges

5.4. Market Opportunities

Chapter 6. Age-Related Macular Degeneration (AMD) Therapeutics Market - By Product

6.1. Eylea

6.2. Lucentis

6.3. Beovu

6.4. Others

Chapter 7. Age-Related Macular Degeneration (AMD) Therapeutics Market -  By Disease Type

7.1. Dry AMD

7.2. Wet AMD

Chapter 8. Age-Related Macular Degeneration (AMD) Therapeutics Market - By Distribution Channel

8.1. Hospital Pharmacy

8.2. Specialty Pharmacy

8.3. Online Pharmacy

Chapter 9. Age-Related Macular Degeneration (AMD) Therapeutics Market – By Region

9.1. North America

9.2. Europe

9.3.The Asia Pacific

9.4.Latin America

9.5. Middle-East and Africa

Chapter 10. Age-Related Macular Degeneration (AMD) Therapeutics Market – Company Profiles – (Overview, Product Portfolio, Financials, Developments)

10.1. Company 1

10.2. Company 2

10.3. Company 3

10.4. Company 4

10.5. Company 5

10.6. Company 6

10.7. Company 7

10.8. Company 8

10.9. Company 9

10.10. Company 10